[

serum institute of india news

]

Latest from serum institute of india

SII's Adar Poonawalla expects Omicron-specific vaccine in 6 months: Report

Adar Poonawalla's statement came even as the UK became the first country to authorise an updated version of Moderna's Covid-19 vaccine that includes protection against the Omicron variant.

Adar Poonawalla, CEO of Serum Institute of India (SII), the world's biggest vaccine maker.(REUTERS file)
Adar Poonawalla, CEO of Serum Institute of India (SII), the world's biggest vaccine maker.(REUTERS file)
Published on Aug 15, 2022 11:36 PM IST
By, New Delhi

Monkeypox: As India sees rise in cases, what Adar Poonawalla said about vaccine

India has so far reported eight cases of monkeypox, of which five have been from Kerala and three from Delhi. Of the five patients in Kerala, one succumbed to the disease on July 30, making it India's first monkeypox fatality.

Adar Poonawalla, chief executive officer of Serum Institute of India Ltd. (Bloomberg)
Adar Poonawalla, chief executive officer of Serum Institute of India Ltd. (Bloomberg)
Published on Aug 02, 2022 05:41 PM IST
Written by Sharangee Dutta | Edited by Aniruddha Dhar, New Delhi

Serum institute seeks government nod to export Covovax to the US

SII manufactures Covovax under a license from the vaccine’s developer, US-based Novavax. The export version of the vaccine is called Nuvaxovid and has been dispatched to New Zealand, Netherlands, Australia and Indonesia, where a total of at least 100 million doses have been sent.

SII chief executive officer Adar Poonawalla. (REUTERS)
SII chief executive officer Adar Poonawalla. (REUTERS)
Published on Jul 01, 2022 03:16 AM IST
By, New Delhi

Govt panel recommends market authorisation for Serum's cervical cancer vaccine

Cervical cancer in India ranks as the second most frequent cancer among women between 15 and 44 years of age.

The SII is also learnt to have made a presentation before the working group of HPV constituted separately by the NTAGI to review the data and usefulness of this vaccine last Wednesday.( representative image)
The SII is also learnt to have made a presentation before the working group of HPV constituted separately by the NTAGI to review the data and usefulness of this vaccine last Wednesday.( representative image)
Published on Jun 15, 2022 10:37 PM IST
PTI |

Covovax gets govt nod for 12-18 age group at private centres

On April 29, the National Technical Advisory Group on Immunisation (NTAGI)--the government’s technical panel--recommended inclusion of Covovax in the vaccination programme for children aged 12 and above.

Currently, while Covishield is available for all adults, Bharat Biotech’s Covaxin is available for those aged 15 and above. Corbevax is being used for children in the 12-15 age group (HT FILE)
Currently, while Covishield is available for all adults, Bharat Biotech’s Covaxin is available for those aged 15 and above. Corbevax is being used for children in the 12-15 age group (HT FILE)
Published on May 03, 2022 11:37 PM IST

'Covovax now available for children in India', says Adar Poonawalla, hails Modi

Serum Institute of India (SII) director for government and regulatory affairs Prakash Kumar Singh had written to the Centre recently requesting for Covovax's inclusion in the immunisation drive for children aged 12 to 17 years.

Adar Poonawalla’s Serum Institute of India locally manufactures the Oxford-AstraZeneca Covid vaccine under the brand name Covishield.(Reuters file)
Adar Poonawalla’s Serum Institute of India locally manufactures the Oxford-AstraZeneca Covid vaccine under the brand name Covishield.(Reuters file)
Updated on May 10, 2022 07:57 PM IST
By, New Delhi

Made in India Covid vaccines better than Pfizer, Moderna: SII's Adar Poonawalla

Speaking to ANI, Poonawalla said, "The Covid-19 vaccines which have been made in India are providing more protection against the disease than mRNA vaccines like Pfizer and Moderna."

On being asked about the export of the Covishield Covid-19 vaccine, Adar Poonawalla
On being asked about the export of the Covishield Covid-19 vaccine, Adar Poonawalla
Published on Apr 13, 2022 04:22 PM IST
ANI |

Covishield booster shots to be priced at 600 plus taxes: Adar Poonawalla

Covovax - which has not been formally announced as a booster shot, will be priced around ₹900 plus taxes, once approved. The vaccine is currently being used to inoculate adults and those in the 12-17 age group in emergency situations.

Covishield has been manufactured by Pune-based Serum Institute of India, which is the world's largest vaccine maker.(Reuters)
Covishield has been manufactured by Pune-based Serum Institute of India, which is the world's largest vaccine maker.(Reuters)
Updated on Apr 08, 2022 06:54 PM IST
By | Written by Sharangee Dutta, New Delhi

Can’t disclose data on trials: Vaccine makers to Supreme Court

Submitting its reply to Puliyel’s petition in November last, the central drugs standard control organization (CDSCO) said that entertaining such a petition would harm public interest.

A student receives a dose of a Covid vaccine in Noida. (HT photo/Sunil Ghosh)
A student receives a dose of a Covid vaccine in Noida. (HT photo/Sunil Ghosh)
Updated on Mar 23, 2022 05:04 AM IST

Give full authorisation to Covishield: Serum Institute of India

Serum Institute of India locally manufactures the Oxford-AstraZeneca Covid-19 vaccine under the brand name Covishield.

Ranchi, Dec 28 (ANI): A beneficiary receives a dose of the COVID-19 vaccine during a door-to-door vaccination programme, at Deoghar, in Ranchi on Tuesday. (ANI Photo) (Somnath Sen)
Ranchi, Dec 28 (ANI): A beneficiary receives a dose of the COVID-19 vaccine during a door-to-door vaccination programme, at Deoghar, in Ranchi on Tuesday. (ANI Photo) (Somnath Sen)
Updated on Dec 31, 2021 11:07 PM IST

Serum Institute of India applies for full approval of Covishield Covid vaccine

Serum Institute, which produces AstraZeneca's Covid-19 vaccine under the brand name Covishield, has supplied more than 1.25 billion doses of the shot in India.

Serum Institute, which is also the world's biggest vaccine maker, was granted approval for emergency use of Covishield in India at the beginning of the year.(Reuters)
Serum Institute, which is also the world's biggest vaccine maker, was granted approval for emergency use of Covishield in India at the beginning of the year.(Reuters)
Published on Dec 31, 2021 01:48 PM IST
Reuters | , Bengaluru

Covovax gets WHO’s nod for emergency use

SII has the license to produce over two billion doses of the vaccine

Covovax is part of the WHO-led Covax facility. SII began stockpiling doses in the summer and a Union health ministry assessment in June said the government expects 200 million doses of the vaccine to be available by December.(HT File)
Covovax is part of the WHO-led Covax facility. SII began stockpiling doses in the summer and a Union health ministry assessment in June said the government expects 200 million doses of the vaccine to be available by December.(HT File)
Published on Dec 18, 2021 02:14 AM IST
By, Hindustan Times, New Delhi

Vaccine maker SII pledges $66 million to Oxford University

The investment was made through the Indian company's Serum Life Sciences unit, Oxford University said on Wednesday.

The research building would be named after Serum's billionaire owners, the Poonawalla family. The pledge builds on the collaboration between Oxford University, AstraZeneca and SII(Reuters)
The research building would be named after Serum's billionaire owners, the Poonawalla family. The pledge builds on the collaboration between Oxford University, AstraZeneca and SII(Reuters)
Published on Dec 15, 2021 05:50 AM IST
Reuters |

Omicron: Will India allow booster dose? Here's what central expert panel said

The Pune-based SII had earlier on December 1 requested the DCGI to authorise Covishield as a booster dose, citing the emergence of new coronavirus variants in the country and an adequate stock of vaccines to tackle that growing concern.

More than 60 countries across the world have already authorised booster doses of the Covid-19 vaccine, said the central government in a written reply to Parliament this week. (Representational Image / AP)
More than 60 countries across the world have already authorised booster doses of the Covid-19 vaccine, said the central government in a written reply to Parliament this week. (Representational Image / AP)
Published on Dec 11, 2021 07:53 AM IST
Written by Joydeep Bose | Edited by Meenakshi Ray, Hindustan Times, New Delhi

Serum Institute seeks DCGI nod for Covishield booster shot amid Omicron scare

In an application to DCGI, Prakash Kumar Singh, director of government and regulatory affairs at Serum Institute of India wrote that there is no shortage of Covishield in India now and the demand for booster dose is rising by each passing day in wake of the emerging new strains of the coronavirus.

Prakash Kumar Singh, director of government and regulatory affairs at Pune-based SII, mentioned in his letter to DCGI that the UK’s Medicines and Healthcare products regulatory agency has already approved the booster doses of AstraZeneca ChAdOx1 nCoV-19 vaccine.(Representational Image / Bloomberg)
Prakash Kumar Singh, director of government and regulatory affairs at Pune-based SII, mentioned in his letter to DCGI that the UK’s Medicines and Healthcare products regulatory agency has already approved the booster doses of AstraZeneca ChAdOx1 nCoV-19 vaccine.(Representational Image / Bloomberg)
Published on Dec 01, 2021 11:15 PM IST
Written by Sharangee Dutta | Edited by Amit Chaturvedi, Hindustan Times, New Delhi

Serum Institute of India resumes exports of Covishield vaccine to COVAX facility

India in March put a temporary hold on all major exports of the AstraZeneca shot made by the family-run firm to inoculate its citizens during a devastating surge in Covid-19 cases.

SII said its supply of doses through COVAX was expected to increase substantially into the first quarter of 2022.(Reuters)
SII said its supply of doses through COVAX was expected to increase substantially into the first quarter of 2022.(Reuters)
Published on Nov 26, 2021 06:24 PM IST
Reuters |

Delay in SII’s first shipment to Nepal under Covax

India halted export of Covid-19 vaccines in April after a severe second wave hit the country that impacted the Covid-19 vaccines global access, or Covax programme, which has been established to deliver Covid-19 vaccines equitably to all countries.

Serum Institute may ship 20-30 million doses of Covishield by the end of the year, the company has said in the past. (AFP)
Serum Institute may ship 20-30 million doses of Covishield by the end of the year, the company has said in the past. (AFP)
Updated on Nov 24, 2021 02:47 AM IST
By, Hindustan Times, New Delhi

Serum Institute to resume supply of Covishield to COVAX: Reports

In April, the Centre halted supply of Covid-19 vaccines to the UN-backed programme as India itself was hit by a severe second wave of the pandemic.

Adar Poonawalla, chief executive officer of Serum Institute of India. (File photo)
Adar Poonawalla, chief executive officer of Serum Institute of India. (File photo)
Published on Nov 23, 2021 11:27 AM IST
By, New Delhi

Govt allows SII to export 5 crore doses of Covid-19 vaccine Covovax to Indonesia

Recently, Prakash Kumar Singh, Director, Government and Regulatory Affairs at SII, wrote to the DCGI seeking no objection certification to export 50 lakh vials of Covovax.

Adar Poonawalla, chief executive officer of Serum Institute of India. (File photo)
Adar Poonawalla, chief executive officer of Serum Institute of India. (File photo)
Published on Nov 15, 2021 11:17 PM IST
PTI | | Posted by Sharangee Dutta, Hindustan Times, New Delhi

Serum Institute of India gets nod for trials of Covovax in children

This makes it the third Covid-19 vaccine to be tested in children in India, after Bharat Biotech’s Covaxin and Zydus Cadila’s ZyCoV-D.

Serum Institute of India received permission to conduct phase II and III clinical trials of Covid vaccine, Covovax, in children between 7 and 11 years of age. (ANI)
Serum Institute of India received permission to conduct phase II and III clinical trials of Covid vaccine, Covovax, in children between 7 and 11 years of age. (ANI)
Updated on Sep 29, 2021 04:43 AM IST
By, New Delhi

Could have immense positive impact: Gavi on India's move to export Covid-19 vax

The global alliance Gavi also said it is keen on collaborating with Serum Institute of India and the health ministry to protect vulnerable people from Covid-19 virus.

India will resume export of Covid-19 vaccines under its ‘Vaccine Maitri’ initiative from October to fulfil the country's commitmment towards COVAX. (File photo / PTI)
India will resume export of Covid-19 vaccines under its ‘Vaccine Maitri’ initiative from October to fulfil the country's commitmment towards COVAX. (File photo / PTI)
Published on Sep 21, 2021 03:46 PM IST
By | Written by Avik Roy, New Delhi

Centre has ordered 66 crore doses of Covishield from SII: Report

SII has been scaling up production by enhancing the manufacturing capacity of Covishield to more than 20 crore doses per month.

Serum Institute of India has also supplied 12 crore doses of Covishield in the month of August, the company said. (HT PHOTO)(HT_PRINT)
Serum Institute of India has also supplied 12 crore doses of Covishield in the month of August, the company said. (HT PHOTO)(HT_PRINT)
Updated on Sep 09, 2021 11:09 PM IST
By, Hindustan Times, New Delhi

20 crore Covishield doses to be supplied in September, SII informs Centre

This is double the number of doses the SII earlier told central government it will deliver in September.

A medical staff prepares a jab of the Covishield, AstraZeneca-Oxford's Covid-19 coronavirus vaccine (AFP).
A medical staff prepares a jab of the Covishield, AstraZeneca-Oxford's Covid-19 coronavirus vaccine (AFP).
Published on Aug 26, 2021 06:25 PM IST
By, New Delhi

SII buys 50% stake in pharma firm that provide glass vials to store Covishield

The Pune-based Serum Institute of India's CEO Adar Poonawalla said in a statement that securing supply chain is of "strategic importance."

The SII has bought the 50 per cent stake in the Indian joint venture SCHOTT Kaisha from former co-owners Kairus Dadachanji and Shapoor Mistry.
The SII has bought the 50 per cent stake in the Indian joint venture SCHOTT Kaisha from former co-owners Kairus Dadachanji and Shapoor Mistry.
Published on Aug 17, 2021 09:41 PM IST
ANI | | Posted by Sharangee Dutta, Hindustan Times, New Delhi

News updates from HT: Serum Institute's Cyrus Poonawalla praises PM Modi

Here are today’s top news, analysis and opinion. Know all about the latest news and other news updates from Hindustan Times.

Cyrus Poonawalla said he had to struggle for basic things like transport, communication.(Livemint File Photo)
Cyrus Poonawalla said he had to struggle for basic things like transport, communication.(Livemint File Photo)
Updated on Aug 13, 2021 08:56 PM IST
By, New Delhi

‘Wasn't supposed to say’: Serum chief praises PM Modi, says no ‘maska polish’

The drug controller responds even after office hours, Cyrus Poonawalla said praising PM Modi's reforms that ended licenceraj. Once he had to fall at the feet of the bureaucrats, the chairman of the world's largest vaccine maker said. 

Cyrus Poonawalla said he had to struggle for basic things like transport, communication. 
Cyrus Poonawalla said he had to struggle for basic things like transport, communication. 
Published on Aug 13, 2021 07:27 PM IST
By | Written by Poulomi Ghosh

News updates from HT: Domestic flights become costlier and all the latest news

Here are today’s top news, analysis, and opinion. Know all about the latest news and other news updates from Hindustan Times.

Image used only for representative purpose
Image used only for representative purpose
Published on Aug 13, 2021 04:51 PM IST
By, New Delhi, Hindustan Times

'Hope to launch Covavax for adults in Oct, early 2022 for kids': Adar Poonwalla

The Serum Institute of India CEO also said that the price of the anti-Covid vaccine will be determined at the time of launch.

Adar Poonawalla (File photo)
Adar Poonawalla (File photo)
Published on Aug 06, 2021 06:53 PM IST
By | Written by Karan Manral, New Delhi

Serum Institute joins hands with CII to accelerate vaccination in rural areas

Speaking on Friday’s development, SII’s chief executive officer (CEO) Adar Poonawalla said the partnership with the Confederation of Indian Industry “will be a good way to close the gaps” as there is plenty of supply of Covishield doses available for distribution.

SII, which is the largest vaccine manufacturer across the globe, has been producing the United Kingdom (UK)-based AstraZeneca vaccine under the brand name of ‘Covishield’ in India.(AFP file photo)
SII, which is the largest vaccine manufacturer across the globe, has been producing the United Kingdom (UK)-based AstraZeneca vaccine under the brand name of ‘Covishield’ in India.(AFP file photo)
Updated on Jul 30, 2021 06:00 PM IST
By | Written by Harshit Sabarwal | Edited by Poulomi Ghosh, New Delhi

News updates from HT: IMD says monsoon revival unlikely before July 7

Here are today’s top news, analysis, and opinion at this hour. Know all about the latest news and other news updates from Hindustan Times.

Monsoon is unlikely to progress over the rest of northwest India till July 7, India Meteorological Department (IMD) said on Wednesday.(HT Photo)
Monsoon is unlikely to progress over the rest of northwest India till July 7, India Meteorological Department (IMD) said on Wednesday.(HT Photo)
Published on Jul 01, 2021 08:50 AM IST
By, Hindustan Times, New Delhi
SHARE
  • 1
  • 2
  • 3
  • ...
Story Saved
×
Saved Articles
Following
My Reads
My Offers
Sign out
New Delhi 0C
Wednesday, October 05, 2022
Start 15 Days Free Trial Subscribe Now
Register Free and get Exciting Deals